A triple vaccine for cats being developed by Taizhou Bioally Technology Co Ltd – located in the Taizhou Medical High-tech Zone in Taizhou city, in East China's Jiangsu province – has proved to be a big hit in the market.
The company reported shipping over 600,000 units in over three months, with orders placed by over 6,000 pet hospitals.
Bioally Technology says its triple vaccine for cats can effectively prevent three core infectious diseases of cats – rhinotracheitis, goblet virus disease and feline plague.
Previously, the domestic market for the triple vaccine for cats was dominated by an American animal health company.
However, statistics showed that from August 2023 to January 2024, there were seven triple vaccine products for cats that passed the national acute response evaluation, with Bioally Technology's product being one of them.
In recent years, in order to accelerate the commercialization of new products, Taizhou Bioally Technology Co has invested 250 million yuan ($34.5 million) to build a research and production facility for pet health in accordance with EU standards.
Focusing on pet health, the company has laid out a full range of products in areas such as blood protein drugs, recombinant gene protein drugs and new drug formulations.
A hit in the market: The triple vaccine for cats being developed by Taizhou Bioally Technology Co. [Photo/cmc.gov.cn]